Skip to content
10-K

Annual Report

SELLAS Life Sciences Group, Inc. SLS

0001390478-26-000003

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 18, 2026 179.58M sh
Shares Diluted FY 2025 · Dec 31, 2025 109.05M sh
Shares Diluted FY 2025 · Dec 31, 2024 61.2M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$28.39M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$35.4M
Cash And Equivalents FY 2025 · Dec 31, 2025 $71.79M
Cash And Equivalents FY 2025 · Dec 31, 2024 $13.89M
Stockholders Equity FY 2025 · Dec 31, 2025 $70.87M
Stockholders Equity FY 2025 · Dec 31, 2024 $9.47M
Stockholders Equity FY 2025 · Dec 31, 2023 −$7.98M
Current Liabilities FY 2025 · Dec 31, 2025 $7.02M
Current Liabilities FY 2025 · Dec 31, 2024 $9.51M
Total Liabilities FY 2025 · Dec 31, 2025 $7.47M
Total Liabilities FY 2025 · Dec 31, 2024 $9.97M
Current Assets FY 2025 · Dec 31, 2025 $75.21M
Current Assets FY 2025 · Dec 31, 2024 $16.33M
Total Assets FY 2025 · Dec 31, 2025 $78.35M
Total Assets FY 2025 · Dec 31, 2024 $19.43M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.25
Eps Diluted FY 2025 · Dec 31, 2024 −$0.50
Eps Basic FY 2025 · Dec 31, 2025 −$0.25
Eps Basic FY 2025 · Dec 31, 2024 −$0.50
Sga Expense FY 2025 · Dec 31, 2025 $12.25M
Sga Expense FY 2025 · Dec 31, 2024 $12.42M
Net Income FY 2025 · Dec 31, 2025 −$26.86M
Net Income FY 2025 · Dec 31, 2024 −$30.88M
Operating Income FY 2025 · Dec 31, 2025 −$28.27M
Operating Income FY 2025 · Dec 31, 2024 −$31.51M